Among these molecular targets, the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway has proved to be an indispensable driving signaling and associated with tumor progression, treatment response, and clinical outcomes in many types of tumors. Here, MTOR is linked to neoplasm.